Welcome to the 116th edition of Deep Tech Catalyst, the educational channel from The Scenarionist where science meets venture!
In this week’s episode of Deep Tech Catalyst, I sat down with Eric Donsky, three-times exited Deep Tech entrepreneur, and today CEO of Atomic13.
In our conversation, we unpacked TearLab’s journey, a venture path at the intersection of Deep Tech and lab-on-a-chip diagnostics, from identifying an overlooked gap in eye care to building a clinically usable biomarker platform, navigating long development timelines, structuring capital around technical uncertainty, and ultimately scaling the company through clinical validation, market adoption, and the public markets.
Key takeaways from the episode:
🎯 The best opportunities often begin where demand is real but not yet explicit
Some of the most valuable Deep Tech companies are built not around markets loudly demanding innovation, but around operational or customer friction that is widespread and poorly solved.
🧩 A product must work for every user in the workflow, not just the buyer
In healthcare especially, adoption depends on solving for multiple stakeholders at once. A technology may be clinically powerful, but it still needs to fit seamlessly into the daily routines, incentives, and constraints of the people expected to use it.
🧪 The invention is only the starting point; the real challenge is building the full system
The scientific insight may define the opportunity, but commercialization depends on solving the interface between science, product architecture, manufacturability, and reliability in real-world use.
💸 In Deep Tech, capital strategy has to reflect delay, iteration, and technical risk
When timelines stretch and technical bottlenecks emerge, undercapitalization becomes one of the fastest ways to destroy optionality. The right capital often comes from investors who understand the problem deeply enough to strengthen more than just the balance sheet.
📈 Technical success does not scale on its own
Clinical evidence, trusted validators, reimbursement logic, and a credible market narrative all matter. In regulated sectors, scaling a company requires much more than proving that the technology works.











